The burden of antimicrobial resistance in the Americas in 2019: a cross-country systematic analysis

Aguilar, Gisela Robles; Swetschinski, Lucien; Weaver, Nicole Davis; Ikuta, Kevin S; Meštrović, Tomislav; Gray, Authia P; Chung, Erin; Wool, Eve; Han, Chieh; Hayoon, Anna Gershberg; Araki, Daniel T.; Abdollahi, Ashkan; Abu‐Zaid, Ahmed; Adnan, Mohammad; Agarwal, Ramesh K.; Dehkordi, Javad Aminian; Aravkin, Aleksandr Y.; Areda, Demelash; Azzam, Ahmed Y; Berezin, Eitan N.; Bhagavathula, Akshaya Srikanth; Bhutta, Zulfiqar A; Bhuyan, Soumitra S.; Browne, Annie J.; Castañeda-Orjuela, Carlos; Chandrasekar, Eeshwar K.; Ching, Patrick R; Dai, Xiaochen; Darmstadt, Gary L.; Hoz, Fernando Pío De la; Diao, Nancy; Díaz, Daniel; Santos, Wendel Mombaque dos; Eyre, David W; Garcia, Coralith; Haines–Woodhouse, Georgina; Hassen, Mohammed Bheser; Henry, Nathaniel J.; Hopkins, Susan; Hossain, Md Mahbub; Iregbu, Kenneth; Iwu, Chidozie C D; Jacobs, Jan; Janko, Mark; Jones, Ronald N.; Karaye, Ibraheem M.; Khalil, Ibrahim; Khan, Imteyaz Ahmad; Khan, Taimoor; Khubchandani, Jagdish; Khusuwan, Suwimon; Kısa, Adnan; Koyaweda, Giscard Wilfried; Krapp, Fiorella; Kumaran, Emmanuelle A. P.; Kyu, Hmwe Hmwe; Lim, Stephen S; Li, Xuefeng; Luby, Stephen P.; Maharaj, Sandeep; Maronga, Christopher; Martorell, Miquel; May, Jürgen; McManigal, Barney; Mokdad, Ali H.; Moore, Catrin E.; Mostafavi, Ebrahim; Murillo-Zamora, Efrén; Mussi-Pinhata, Marisa Márcia; Nanavati, Ruchi; Nassereldine, Hasan; Natto, Zuhair S.; Qamar, Farah Naz; Núñez-Samudio, Virginia; Ochoa, Theresa J.; Ojo-Akosile, Tolulope R.; Olagunju, Andrew T; Olivas-Martínez, Antonio; Ortíz-Brizuela, Edgar; Ounchanum, Pradthana; Paredes, José Luís; Patthipati, Venkata Suresh; Pawar, Shrikant; Pereira, Marcos; Pollard, Andrew J.; Ponce-de-León, Alfredo; Prates, Elton Junio Sady; Qattea, Ibrahim; Reyes, Luis Felipe; Roilides, Emmanuel; Rosenthal, Victor; Rudd, Kristina E.; Sangchan, Weerawut; Seekaew, Samroeng; Seylani, Allen; Shababi, Niloufar; Sham, Sunder; Sifuentes–Osornio, José; Singh, Harpreet; Stergachis, Andy; Tasak, Nidanuch; Tat, Nathan Y; Thaiprakong, Areerat; Valdez, Pascual; Yada, Dereje Y.; Yunusa, Ismaeel; Застрожин, Михаил Сергеевич; Hay, Simon I.; Dolecek, Christiane; Sartorius, Benn; Murray, Christopher J L; Naghavi, Mohsen

doi:10.1016/j.lana.2023.100561

Cited by 18 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding holds relevance for a region where the kidney disease burden is substantial. 77 Moreover, considering the complex dosing requirements and close monitoring associated with colistin plus meropenem, along with the region’s higher prevalence of carbapenemase-producing Enterobacterales 78 79 and antibiotic-resistant gram-negative pathogens, 80 the potential for expanded treatment coverage is substantial.…”

Section: Discussionmentioning

confidence: 99%

Costs-effectiveness and cost components of pharmaceutical and non-pharmaceutical interventions affecting antibiotic resistance outcomes in hospital patients: a systematic literature review

Allel,

Hernández-Leal,

Naylor

et al. 2024

BMJ Glob Health

View full text Add to dashboard Cite

IntroductionLimited information on costs and the cost-effectiveness of hospital interventions to reduce antibiotic resistance (ABR) hinder efficient resource allocation.MethodsWe conducted a systematic literature review for studies evaluating the costs and cost-effectiveness of pharmaceutical and non-pharmaceutical interventions aimed at reducing, monitoring and controlling ABR in patients. Articles published until 12 December 2023 were explored using EconLit, EMBASE and PubMed. We focused on critical or high-priority bacteria, as defined by the WHO, and intervention costs and incremental cost-effectiveness ratio (ICER). Following Preferred Reporting Items for Systematic review and Meta-Analysis guidelines, we extracted unit costs, ICERs and essential study information including country, intervention, bacteria-drug combination, discount rates, type of model and outcomes. Costs were reported in 2022 US dollars ($), adopting the healthcare system perspective. Country willingness-to-pay (WTP) thresholds from Woodset al2016 guided cost-effectiveness assessments. We assessed the studies reporting checklist using Drummond’s method.ResultsAmong 20 958 articles, 59 (32 pharmaceutical and 27 non-pharmaceutical interventions) met the inclusion criteria. Non-pharmaceutical interventions, such as hygiene measures, had unit costs as low as $1 per patient, contrasting with generally higher pharmaceutical intervention costs. Several studies found that linezolid-based treatments for methicillin-resistantStaphylococcus aureuswere cost-effective compared with vancomycin (ICER up to $21 488 per treatment success, all 16 studies’ ICERs<WTP). Infection control measures such as hand hygiene and gown usage (ICER=$1160/QALY or $4949 per ABR case averted, all ICERs<WTP) and PCR or chromogenic agar screening for ABR detection were highly cost-effective (eg, ICER=$1206 and $1115 per life-year saved in Europe and the USA). Comparisons were hindered by within-study differences.ConclusionRobust information on ABR interventions is critical for efficient resource allocation. We highlight cost-effective strategies for mitigating ABR in hospitals, emphasising substantial knowledge gaps, especially in low-income and middle-income countries. Our study serves as a resource for guiding future cost-effectiveness study design and analyses.PROSPERO registration numberCRD42020341827 and CRD42022340064

show abstract

Section: Discussionmentioning

confidence: 99%

Costs-effectiveness and cost components of pharmaceutical and non-pharmaceutical interventions affecting antibiotic resistance outcomes in hospital patients: a systematic literature review

Allel,

Hernández-Leal,

Naylor

et al. 2024

BMJ Glob Health

View full text Add to dashboard Cite

show abstract

“…Aguilar et al [ 52 ] estimated that in 2019, AMR was linked to approximately 569,000 deaths (95% UI 406,000–771,000) and about 141,000 deaths (99,900–196,000) were connected to bacterial AMR in the 35 countries within the World Health Organization’s Region of the Americas. The six leading pathogens (by order of number of deaths associated with resistance) are S. aureus , Escherichia coli , K. pneumoniae , Streptococcus pneumoniae , Pseudomonas aeruginosa , and A. baumannii .…”

Section: Discussionmentioning

confidence: 99%

Bibliometric Analysis of Global Research Output on Antimicrobial Resistance among Pneumonia Pathogens (2013–2023)

Ablakimova,

Smagulova,

Rachina

et al. 2023

Antibiotics

View full text Add to dashboard Cite

Antimicrobial resistance (AMR) is a pressing global concern, posing significant challenges to the effective treatment of infections, including pneumonia. This bibliometric analysis aims to investigate the research output on AMR among pneumonia pathogens from 2013 to 2023. Data were extracted from the Web of Science Core Collection (WOS-CC) using an inclusive search strategy. The analysis included 152 relevant studies published in 99 different sources, involving 988 authors and yielding an average of 16.33 citations per document over the past decade. The findings reveal a notable increase in research on AMR among pneumonia pathogens, indicating a growing awareness of this critical issue. Collaborative studies were prevalent, with the majority of authors engaging in joint research efforts. Bradford’s Law identified twelve core journals that were instrumental in disseminating research in this field, with “Medicine” emerging as the most prolific journal. The USA and China emerged as the leading contributors, while Germany displayed a strong inclination towards collaborative research. Intermountain Medical Center, Saitama Medical University, and Udice-French Research Universities were the most productive institutions, and Yayan J. and Rasche K. were the top authors. Furthermore, the analysis identified commonly encountered microorganisms such as Acinetobacter baumanii and Klebsiella pneumoniae in the context of AMR. Time-based analysis of keywords highlighted the significance of terms like “community-acquired pneumonia” and “ventilator-associated pneumonia”. Overall, this comprehensive study sheds light on the global research landscape of AMR among pneumonia pathogens. The insights gained from this analysis are essential for guiding future research priorities and collaborative efforts to combat AMR effectively and improve treatment outcomes for pneumonia and related infections. As the frequency of reports concerning resistance among pneumonia pathogens, notably A. baumannii and K. pneumoniae, continues to rise, there is an immediate requirement for pharmaceutical manufacturers and healthcare providers to respond proactively and ready themselves for the forthcoming implications of this matter. It also underscores the importance of knowledge dissemination and evidence-based interventions to address this growing public health challenge. However, the study acknowledges the limitations associated with using a single publication database and encourages the inclusion of data from other sources in future research.

show abstract

“…Furthermore, an estimated 4.95 million deaths were associated with bacterial AMR ( Murray et al., 2022 ). Specifically, it was reported that 569,000 deaths (with a 95% UI of 406,000-771,000) were linked to bacterial AMR, and an additional 141,000 deaths (ranging from 99,900 to 196,000) were attributable to bacterial AMR within the 35 countries situated in the WHO Region of the Americas during the same year ( Aguilar et al., 2023 ). It is worth noting that mortality related to antibiotic resistance has now escalated to become the third most prominent cause of death on a global scale ( Murray et al., 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Bacteriophage therapy for drug-resistant Staphylococcus aureus infections

Liu,

Wang,

Zhou

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Drug-resistant Staphylococcus aureus stands as a prominent pathogen in nosocomial and community-acquired infections, capable of inciting various infections at different sites in patients. This includes Staphylococcus aureus bacteremia (SaB), which exhibits a severe infection frequently associated with significant mortality rate of approximately 25%. In the absence of better alternative therapies, antibiotics is still the main approach for treating infections. However, excessive use of antibiotics has, in turn, led to an increase in antimicrobial resistance. Hence, it is imperative that new strategies are developed to control drug-resistant S. aureus infections. Bacteriophages are viruses with the ability to infect bacteria. Bacteriophages, were used to treat bacterial infections before the advent of antibiotics, but were subsequently replaced by antibiotics due to limited theoretical understanding and inefficient preparation processes at the time. Recently, phages have attracted the attention of many researchers again because of the serious problem of antibiotic resistance. This article provides a comprehensive overview of phage biology, animal models, diverse clinical case treatments, and clinical trials in the context of drug-resistant S. aureus phage therapy. It also assesses the strengths and limitations of phage therapy and outlines the future prospects and research directions. This review is expected to offer valuable insights for researchers engaged in phage-based treatments for drug-resistant S. aureus infections.

show abstract

The burden of antimicrobial resistance in the Americas in 2019: a cross-country systematic analysis

Cited by 18 publications

References 26 publications

Costs-effectiveness and cost components of pharmaceutical and non-pharmaceutical interventions affecting antibiotic resistance outcomes in hospital patients: a systematic literature review

Costs-effectiveness and cost components of pharmaceutical and non-pharmaceutical interventions affecting antibiotic resistance outcomes in hospital patients: a systematic literature review

Bibliometric Analysis of Global Research Output on Antimicrobial Resistance among Pneumonia Pathogens (2013–2023)

Bacteriophage therapy for drug-resistant Staphylococcus aureus infections

Contact Info

Product

Resources

About